Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04334759
Title DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma (DREAM3R)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors PrECOG, LLC.
Indications

malignant pleural mesothelioma

Therapies

Durvalumab

Cisplatin + Pemetrexed Disodium

Cisplatin + Durvalumab + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.